A rapid HPLC method for the quantification of 3,5,4′-trimethoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study

被引:48
作者
Lin, Hai-Shu [1 ]
Ho, Paul C. [1 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Singapore 119260, Singapore
关键词
3,5,4 '-trimetlioxy-tratis-stilbene; HPLC; UV detection; Pharmacokinetics; LOW BIOAVAILABILITY; AQUEOUS SOLUBILITY; TRANS-RESVERATROL; 3,5,4'-TRIMETHOXYSTILBENE; CANCER; INHIBITION; METABOLISM; ABSORPTION; ANALOGS; CELLS;
D O I
10.1016/j.jpba.2008.10.042
中图分类号
O65 [分析化学];
学科分类号
070302 [分析化学];
摘要
A rapid HPLC-UV method had been developed and validated to quantify 3,5,4'-trimethoxy-trans-stilbene (TMS), a naturally occurring and pharmacologically active analog of resveratrol in rat plasma. The samples were mixed with three volumes of acetonitrile to precipitate protein. Chromatographic separation was achieved on a RP-HPLC column (Agilent ZORBAX Eclipse Plus C18: 250 mm x 4.6 mm i.d., 5 mu m), which was protected by a guard column (Agilent ZORBAX Eclipse Plus C18: 12.5 mm x 4.6 mm W., 5 km) through isocratic delivery of a mobile phase of acetonitrile: water (75:25, v/v) at a flow rate of 1.2 ml/min. The assay was executed at 30,C and the UV absorbance at 320 nm was monitored. The retention time of TMS and trans-stilbene (internal standard) was 6.5 and 8.3 min, respectively. The calibration curve was linear within the range of 15-1000 ng/ml (R-2 > 0.998) and 15 ng/ml was the lower LOQ. The intra- and inter-day precisions were good and the RSD was all lower than 7.3%. The mean absolute recovery of TMS in plasma ranged from 99.2 to 104.1%. This HPLC method had been successfully applied to study the pharmacokinetics of TMS, which was fully dissolved with hydroxypropyl-p-cyclodextrin (HP-beta-CyD). In comparison with resveratrol, TMS had greater plasma exposure, longer elimination half-life and lower clearance. As TMS had superior pharmacokinetic characteristics, its potential as a preventive or therapeutic agent in resveratrol-effective conditions or diseases should be considered. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:387 / 392
页数:6
相关论文
共 23 条
[1]
[Anonymous], SCIFINDER SCHOLAR VE
[2]
Inhibition of cancer growth by resveratrol is related to its low bioavailability [J].
Asensi, M ;
Medina, I ;
Ortega, A ;
Carretero, J ;
Baño, MC ;
Obrador, E ;
Estrela, JM .
FREE RADICAL BIOLOGY AND MEDICINE, 2002, 33 (03) :387-398
[3]
Bader Y, 2008, ONCOL REP, V19, P801
[4]
Therapeutic potential of resveratrol:: the in vivo evidence [J].
Baur, Joseph A. ;
Sinclair, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :493-506
[5]
Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′-trimethoxystilbene [J].
Belleri, M ;
Ribatti, D ;
Nicoli, S ;
Cotelli, F ;
Forti, L ;
Vannini, V ;
Stivala, LA ;
Presta, M .
MOLECULAR PHARMACOLOGY, 2005, 67 (05) :1451-1459
[6]
ISOLATION OF 3,4',5-TRIMETHOXY-TRANS-STILBENE OTOBAENE AND HYDROXYOTOBAIN FROM VIROLA CUSPIDATA [J].
BLAIR, GE ;
CASSADY, JM ;
ROBBERS, JE ;
TYLER, VE ;
RAFFAUF, RF .
PHYTOCHEMISTRY, 1969, 8 (02) :497-&
[7]
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent [J].
Boocock, David J. ;
Faust, Guy E. S. ;
Patel, Ketan R. ;
Schinas, Anna M. ;
Brown, Victoria A. ;
Ducharme, Murray P. ;
Booth, Tristan D. ;
Crowell, James A. ;
Perloff, Marjorie ;
Gescher, Andreas J. ;
Steward, William P. ;
Brenner, Dean E. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (06) :1246-1252
[8]
The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol [J].
Das, Surajit ;
Lin, Hai-Shu ;
Ho, Paul C. ;
Ng, Ka-Yun .
PHARMACEUTICAL RESEARCH, 2008, 25 (11) :2593-2600
[9]
Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified β-cyclodextrins [J].
Lin, Hai-Shu ;
Leong, Wendy Wen Yi ;
Yang, Jie An ;
Lee, Pei ;
Chan, Sui Yung ;
Ho, Paul C. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 341 (1-2) :238-245
[10]
Lin HS, 2000, J CLIN PHARM THER, V25, P265